Literature DB >> 2429756

Immunohistochemistry of the blood group A,B,H isoantigens and Oxford Ca antigen as prognostic markers for stage IB squamous cell carcinoma of the cervix.

A C To, S J Soong, H M Shingleton, H Gore, J A Wilkerson, K D Hatch, D Phillips, J R Dollar.   

Abstract

Currently, there is lack of a histologic classification of squamous cell carcinoma of the cervix that correlates significantly with patient survival. This study investigated the survival predictive value of two immunohistochemical markers, the blood group A,B,H isoantigens and the Oxford Ca antigen, on conventional histologic sections of tumor tissues from 85 surgically treated patients with Stage IB squamous cell cervical cancer. The results indicated that the two antigens are two distinct markers, neither of which correlates with tumor grade. The expression of the A,B,H isoantigens is significantly related to patient survival after adjustment for the depth of stromal invasion of the tumor, whereas the Oxford Ca antigen has no survival predictive value.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2429756     DOI: 10.1002/1097-0142(19861201)58:11<2435::aid-cncr2820581114>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Semiquantitative immunohistochemical studies of blood group antigen A, B, H, Le(a), Le(b) structures and Ii backbone chains in the normal human cervix and in cervical adenocarcinoma.

Authors:  N R Griffin; M Wells
Journal:  Histochem J       Date:  1993-03

2.  Prognostic value of ABO blood group in patients with early stage cervical cancer treated with radical hysterectomy with pelvic node dissection.

Authors:  Jitti Hanprasertpong; Ingporn Jiamset; Thiti Atjimakul
Journal:  Tumour Biol       Date:  2015-12-17

3.  Losses of expression of the antigens A, Lea and Lex and over-expression of Ley in carcinomas and HG-SIL of the uterine cervix.

Authors:  Ernesto Moro-Rodríguez; Emilio Alvarez-Fernández
Journal:  Diagn Pathol       Date:  2008-09-11       Impact factor: 2.644

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.